Bharat Biotech, which developed the drug that has shown an efficacy of 81% in the initial phase 3 trial analysis, would submit the clinical trial data to the government in the coming days for review, said a senior official at CDSCO, which is under the Drugs Controller General of India (DCGA).from Top India News- News18.com
Read The Rest:news18..
